Swedish Cancer Institute (SCI)

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Colorectal cancer1 trial
• Endometrial cancer1 trial
• Follicular lymphoma1 trial
• Gastric and oesophageal cancer1 trial
• Liver and biliary tract cancer1 trial
• Lung cancer1 trial
• Mantle cell lymphoma1 trial
• Metastatic breast cancer1 trial
• Ovarian cancer1 trial
• Pancreatic cancer1 trial

Phase

• Phase 12 trials
• Phase 31 trial

Status

• Active, not recruiting1 trial
• Recruiting1 trial
• Withdrawn1 trial

Lead sponsor

• Eli Lilly and Company2 trials
• LeonaBio1 trial

Running trials

• Recruiting

  A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  NCT07101328· Phase 1· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

  NCT06607185· Phase 1· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Follicular lymphoma1 recruiting
• Mantle cell lymphoma1 recruiting

Closed trials

• Recruiting

  Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

  NCT05696626· Phase 3· LeonaBio· Source

  Contact: Simon Daggett - Senior Vice President, Clinical Operations